Nonagen Bioscience Corporation is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary diagnostic, prognostic and monitoring tests designed to address the unmet needs in certain cancers. Our first commercial product, Oncuria™, is focused on early bladder cancer detection. 



Bladder cancer is among the five most common malignancies worldwide. In the US alone, new bladder cancer cases number approximately 81,190 with an estimated 17,240 deaths. Both the absolute numbers of cases and deaths from bladder cancer have increased by 45 and 35%, respectively, since 2002. Bladder cancer ranks as the fourth most common cancer in men affecting males at a higher rate than females (4:1) and the 8th most common cause of cancer deaths in men and women in the US. Five year survival rate for non-muscle invasive (superficial) bladder cancers is 94%, but decreases to 46% and 6% respectively for muscle-invasive bladder cancer and disseminated disease stages. Crucially, more than 70% of patients with treatable bladder cancer will have a recurrence during the first two years after diagnosis. If left untreated, these initially non-muscle invasive lesions can progress to being muscle invasive and therefore life-threatening. Therefore, once treated, bladder cancer patients are under continued surveillance with routine cystoscopy examinations (approximately 1 million performed annually) and cytology (approximately 1.5 million performed annually) for early detection of new bladder cancer. The recurrence phenomenon of bladder cancer makes bladder cancer one of the most prevalent cancers, and the most expensive cancer from diagnosis to death in the US.  

 For patients presenting with blood in their urine or patients with a history of bladder cancer on tumor surveillance, an additional diagnostic test, such as Oncuria™ may provide clarity.  By providing additional information, Oncuria™ may be able to help minimize patient anxiety and reduce overall health costs. Nonagen's current clinical trials are designed to assess Oncuria™ in these settings.    



Nonagen's intellectual property portfolio includes 4 issued and pending patents. Our Oncuria™ Technology utilizes in-licensed technologies which were discovered and developed at R&D Systems and Luminex Corporation, leaders in the field of multiplexed diagnostics. 


Investor Relations:
Dave Mori